Global Market Study on Anticancer Drugs: Targeted Therapy Drug Class Anticipated to Exhibit Highest Revenue Contribution Through 2026

Anticancer Drugs  Market
  • Published On : Sep-2018 |
  • Pages : 274 Pages |
  • Format : Anticancer Drugs  Market Anticancer Drugs  Market Anticancer Drugs  Market Anticancer Drugs  Market

Anticancer, or antineoplastic drugs, are indicated in the treatment of malignancies. Cancer is characterized by the rapid explosion of abnormal cells beyond their boundaries, and invading adjoining organs resulting ultimately in death. According to the world health organization cancer is a leading cause of death worldwide, accounting for 8.8 million deaths in 2015. The most common cancers were lung (1.69 million deaths), colorectal (774 000 deaths), and breast (571 000 deaths). Chemically anticancer drugs are classified as alkylating agents, antimetabolites, natural products, and hormones. Their therapeutic classification include cytotoxic, hormonal therapy, and targeted therapy. Anticancer targeted therapy is further classified into monoclonal antibodies and small molecule inhibitors.

The global anticancer drugs market report provides the market size and forecast for anticancer drugs. The global report on the anticancer drugs market provides market size (US$) and opportunity assessment for anticancer drugs for 2018–2026 by product type and end users. The global anticancer drugs market report also provides qualitative analysis in terms of market dynamics and future growth opportunities for the manufacturers of anticancer drugs across the globe.

Market Value and Forecast

PMR estimates that the global market for anticancer drugs is expected to be valued at US$ 227,192.2 Mn by 2026 end, expanding at a CAGR of 7.4 % over 2018–2026. Targeted therapy is expected to be the leading revenue generating segment in the global anticancer drugs market with approximately 58.2% revenue share in 2018. Monoclonal antibodies anticancer drugs revenues are expected to follow the similar trend over the forecast period. North America is the expected to be the dominant regional anticancer drugs market for anticancer drugs in terms of revenues as well as drug discoveries. North America regional anticancer drugs market revenues are expected to expand at a healthy CAGR of 7.6% over the forecast period of 2018–2026.

Market Dynamics

The global anticancer drugs market is expected to be driven by rise in incidence of cancer, growing healthcare expenditure and improved infrastructure for drug development. The increasing risk factors such as exposure to carcinogens, tobacco and alcohol use, sedentary lifestyles and infections is driving a large cancer burden. The world health organization estimates that almost 15% of cancers worldwide are caused by carcinogenic infections by causative organisms such as Helicobacter pylori, Human papillomavirus (HPV), Hepatitis B virus, Hepatitis C virus, and Epstein-Barr virus.

Likewise, the increasing success of treatments exhibited by the increasing survival rates is the other factor expected to drive the growth of the anticancer drugs market. The advent of targeted therapy is increasing adoption of anticancer drugs owing to their reduced side effects.

Likewise, favorable reimbursements and the shift of cancer towards developing countries owing to rise in risk factors such as industrialization, sedentary lifestyles, exposure to carcinogens are some of the other key factors expected to propel the revenue growth of the anticancer drugs market.

Additionally, growing awareness regarding early diagnosis and treatment has directed the anticancer drugs market to grow at a significant rate. The developing healthcare infrastructure, government initiatives and healthcare investments are the other factors expected to contribute to the revenue growth of the anticancer drugs market.

Besides, increasing out-of-pocket healthcare expenditure in both developing and developed economies and the development of large cancer specialty hospitals are also expected to boost the growth of the market for anticancer drugs. The growing awareness of breast cancer, improvements in survival rise in women’s income is another driver of the global anticancer drugs market. However, high cost of anti-cancer drugs, serious side effects, poor quality of life after treatment, and low survival rate owing to difficult to treat cancers such as lung cancer are factors expected to restrict the growth of the global anticancer drugs market over the forecast period.

Key Regions

The global market for anticancer drugs is segmented in to five key regions viz. North America, Latin America, Europe, Asia Pacific excluding Japan, Japan and Middle East and Africa (MEA).

North America dominated the global anticancer drugs market accounting a leading share in 2017, and is expected to witness rapid growth over the forecast period. The North America market is dominated by the U.S. owing to its larger economy, attractive reimbursement and larger prevalence of cancers.

Europe, is expected to be led by Germany. The U.K., and France, are other prominent countries expected to witness significant growth in the global market owing to large presence of key players. There has been a definite shift of the diseases towards the Asia Pacific regions such as China, and India. Increase disease incidence in developing regions has increased the market attractiveness of the global market for anticancer drugs owing to higher demand. China and India are driving a large revenue market owing to unmet needs and the high mortality rates of cancer in the region.

Africa region have a lower incidence of cancers. The Middle East and Africa market is expected to be dominated by the gulf economies owing to their high income and growing expanse of healthcare.

Key Players

The global market for anticancer drugs is dominated by the a few key players, contributing more than 70% of the market share. The key players operating in the global anticancer drugs market are AbbVie Inc., Bayer, Pfizer Inc., Bristol-Myers Squibb, Roche Holding AG, Eli Lilly & Co, Novartis AG, Astra Zeneca, Johnson & Johnson, and Celgene, among others. Launching new products and acquisitions are the key strategies adopted by the key players in the anticancer drugs market. Research and development collaboration among players coupled with the FDA’s fast track approval for life saving conditions is driving a large market enthusiasm. Many players are investing in biologics research and development to overcome the drawbacks of traditional small molecule anticancer drugs such as side effects, lower selectivity for cancerous cells and their lower efficacy and effectiveness. Targeted drug therapy exploits the qualitative differences between cancer and normal cells resulting in lower side effects and greater efficacy and effectiveness.

Report Description

This Persistence Market Research (PMR) report examines the global anticancer drugs market for the period 2013–2026. The primary objective of the report is to offer insights into market opportunities for anticancer drugs and developments in the anticancer drugs market.

The global anticancer drugs market is expected to yield impressive gains owing to the increasing prevalence of cancer. According to the World Health Organization, the number of global cancer deaths is projected to increase by 45% by 2030, with 70% of the cancer deaths expected to occur in low and middle income countries. Mortality from cancer is projected to reach over 13 million in 2030, while, the number of new cancer cases is expected to increase more than 80% in low-income countries, almost double the 40% rate anticipated in high-income countries by 2030.

The global anticancer drugs market has witnessed a paradigmatic shift from administering highly toxic drugs to targeted personalized therapy with lower side effects. There is an upsurge in adoption of biologics especially monoclonal antibodies. New drug development has achieved high importance owing to emergence of difficulties to treat cancers such as small cell lung cancer. The increase in the number of clinical trials coupled with the growing research and development expenditures has resulted in an buildup of impressive new drug pipeline, which is expected to confer large future market equity for the global anticancer drugs market.

The improvement in the survival rate of cancers, e.g., prostrate and breast, is expected to increase the adoption of cancer treatment, which consequently is expected to drive the growth of the global anticancer drugs market. However, lung cancer is expected to be the single large and most attractive market opportunity owing to its large diseases prevalence and poor patient survival rates especially in the advanced stages. The market for global anticancer drugs is also being driven by the advancements in diagnostics and the growing screening rates. Early detection has been the historical holy grail of cancer treatment owing to its impact on survival rates. Advancements and availability of diagnostics such as computed tomography, nuclear medicine are also expected to fuel revenue growth of the anticancer drugs market.

The Global Anticancer Drugs Market has been Segmented Based on:

  • Drug Class
  • Indications
  • Distribution Channels
  • Regions

The report analyzes the global anticancer drugs market in terms of value (US$ Mn). The report begins with the market definition and explaining different types of drug class and indications for their use. This section also explains the prevalence of different types of cancers across the key regions. The market view point section includes PMR’s analysis on the key trends, drivers, opportunities, trends and macro factors influencing the global anticancer drugs market. Opportunity analysis provided in the section allows clients to better equip with crystal clear decision-making insights.

The report analyzes the anticancer drugs market based on regions and presents the forecast in terms of value (US$ Mn) for the next 08 years. The regions covered in the report include:

  • North America
  • Latin America
  • Europe
  • Asia-Pacific Excluding Japan
  • Middle East & Africa
  • Japan

Each of the section analyzes the regional market by drug class, indications and distribution channel and region. The regional introductory section provides key insights on the market dynamics for each region. The section is mainly designed to provide current scenario of the anticancer drugs market and forecast for 2018–2026. The representative market participants section gives the list of companies operating in each region, competitive landscape and intensity map of their presence in each region.

To arrive at the market value, we have used our in-house proprietary model to estimate the anticancer drugs market value. We have adopted bottom-up approach to forecast the anticancer drugs market. Weighted average selling price is considered to estimate the market value of various drug class mentioned in the scope of the report. The country price is captured with the local currency. The local currency figures are then converted to US$ to offer forecasts in a consistent currency standard. Furthermore, PMR has also considered the latest annual exchange rate to reflect the impact of the most recent economic conditions of a country. Prices considered in the models are standardized based on the average of various drug class.

The revenue forecast presented in the report provides total revenue of the currently available anticancer drugs over 2013–2026. In addition, we have taken into consideration the year-on-year growth to understand the predictability of the market and to identify the right growth opportunities in the global market.

In the next section of the report, the ‘Competitive Landscape’ is included to provide report audiences with a dashboard view and to access the key differentiators among the competitor firms. The market structure analysis provides tier-wise breakdown of the total market revenue. The section also provides company share analysis and brand share analysis for the key market players. This section is primarily designed to provide clients with an objective and detailed comparative assessment of product offerings and strategies of key providers specific to the market segments. Detailed profiles of players operating in the global anticancer drugs market are also provided in the report, which highlight company description, overview, product/segment overview, SWOT analysis, financial information, key developments related to market and strategic overview.

The next section of report analyzes the anticancer drugs market based on drug class and presents the forecast in terms of value for the next 8 years. The drug class covered in the report include:

  • Cytotoxic
  • Hormonal Therapy
  • Targeted Therapy
    • Monoclonal antibodies
    • Small molecule inhibitors

The targeted therapy segment is expected to be the largest segment in the global anticancer drugs market by drug class. The targeted therapy segment is followed by cytotoxic segment which has been the traditional treatment for cancer. The attractive advantages of targeted therapy such as greater selectivity, efficacy and effectiveness confers faster cure rates concurrent with lower side effects, which is the holy grail of anticancer drugs market.

The next section of report analyzes the anticancer drugs market based on distribution channel for anticancer drugs products and provides forecast in terms of value for the next 8 years. The distribution channels covered in the report include:

  • Hospital Pharmacies
  • Retail Pharmacies

Another key feature of this report is the analysis of the key segments in terms of absolute dollar opportunity. This is traditionally overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective of the products. To understand the key growth segments, Persistence Market Research provides the ‘Attractiveness Index’ analysis, which helps to identify the real market opportunities.

Companies covered in Anticancer Drugs Market Report

Company Profiles

  • F. Hoffmann-La Roche Ltd
  • Roche Holding AG
  • Celgene Corp
  • Novartis AG
  • Bristol-Myers Squibb Co
  • Johnson & Johnson
  • Merck & Co.
  • Eli Lilly and Company
  • AstraZeneca plc
  • Amgen Inc..
  • Others.
Back To Top